Drug Discovery for Duchenne Muscular Dystrophy via Utrophin Promoter Activation Screening
Open Access
- 20 October 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (10), e26169
- https://doi.org/10.1371/journal.pone.0026169
Abstract
Duchenne muscular dystrophy (DMD) is a devastating muscle wasting disease caused by mutations in dystrophin, a muscle cytoskeletal protein. Utrophin is a homologue of dystrophin that can functionally compensate for its absence when expressed at increased levels in the myofibre, as shown by studies in dystrophin-deficient mice. Utrophin upregulation is therefore a promising therapeutic approach for DMD. The use of a small, drug-like molecule to achieve utrophin upregulation offers obvious advantages in terms of delivery and bioavailability. Furthermore, much of the time and expense involved in the development of a new drug can be eliminated by screening molecules that are already approved for clinical use. We developed and validated a cell-based, high-throughput screening assay for utrophin promoter activation, and used it to screen the Prestwick Chemical Library of marketed drugs and natural compounds. Initial screening produced 20 hit molecules, 14 of which exhibited dose-dependent activation of the utrophin promoter and were confirmed as hits. Independent validation demonstrated that one of these compounds, nabumetone, is able to upregulate endogenous utrophin mRNA and protein, in C2C12 muscle cells. We have developed a cell-based, high-throughput screening utrophin promoter assay. Using this assay, we identified and validated a utrophin promoter-activating drug, nabumetone, for which pharmacokinetics and safety in humans are already well described, and which represents a lead compound for utrophin upregulation as a therapy for DMD.Keywords
This publication has 63 references indexed in Scilit:
- Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx miceProceedings of the National Academy of Sciences, 2010
- Functional Substitution by TAT-Utrophin in Dystrophin-Deficient MicePLoS Medicine, 2009
- Targeting Artificial Transcription Factors to the Utrophin A PromoterJournal of Biological Chemistry, 2008
- A Specific Mechanism for Nonspecific Activation in Reporter-Gene AssaysACS Chemical Biology, 2008
- MyoD inhibits Fstl1 and Utrn expression by inducing transcription of miR-206The Journal of cell biology, 2006
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004
- NabumetoneDrugs, 2004
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003